Effects of empagliflozin on progression of chronic kidney disease: a pre-specified secondary analysis from the EMPA-KIDNEY trial

HAYNES R., HERRINGTON W., STAPLIN N., Judge P., EMBERSON J., PREISS D., Mayne K., SAMMONS E., ZHU D., HILL M., STEVENS W., WALLENDSZUS K., LANDRAY M., BAIGENT C.

Type

Journal article

Journal

Lancet Diabetes and Endocrinology

Publisher

Elsevier

Publication Date

25/10/2023

Permalink